InxMed Publishes Promising Clinical Data for Colorectal Cancer Drug Combination in The Lancet Oncology

Biotechnology firm InxMed released peer-reviewed research in The Lancet Oncology highlighting strong antitumor activity from a combination therapy targeting KRAS G12C mutations in metastatic colorectal cancer.

28 Aug, 11:16 — 28 Aug, 11:16

Post Share

Sources

Showing 1 of 1 sources

morningstar1d ago

InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation - Morningstar

InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation Morningstar

Read full article →

PERSPECTA

PERSPECTA

InxMed Publishes Promising Clinical Data for Colorectal Cancer Drug Combination in The Lancet Oncology

Sources

InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation - Morningstar

Related Stories

Fed Chair Warsh signals rate hikes as inflation stays elevated

OpenAI Ends Partnership With SpaceX-Owned Coding Tool Cursor

College Dropout Turns Full-Time Pokémon Card Reseller With $7.8M in Sales

Temasek Backs Singapore Airlines’ Strategic Investment in Air India

PERSPECTA